Galectin-9 promotes natural killer cells activity via interaction with CD44

被引:22
|
作者
Rahmati, Amirhossein [1 ]
Bigam, Steven [1 ]
Elahi, Shokrollah [1 ,2 ,3 ]
机构
[1] Univ Alberta, Sch Dent, Div Fdn Sci, Edmonton, AB, Canada
[2] Univ Alberta, Dept Oncol, Edmonton, AB, Canada
[3] Univ Alberta, Li Ka Shing Inst Virol, Fac Med & Dent, Edmonton, AB, Canada
来源
FRONTIERS IN IMMUNOLOGY | 2023年 / 14卷
基金
加拿大健康研究院;
关键词
galectin-9; cancer; COVID-19; cytotoxic effector molecules; cytokines; T-CELLS; NK-CELL; IFN-GAMMA; TIM-3; EXPRESSION; HIV-INFECTION; RECEPTOR; BINDING; DOMAIN; GENE; STIMULATION;
D O I
10.3389/fimmu.2023.1131379
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Natural killer (NK) cells are a potent innate source of cytokines and cytoplasmic granules. Their effector functions are tightly synchronized by the balance between the stimulatory and inhibitory receptors. Here, we quantified the proportion of NK cells and the surface presence of Galectin-9 (Gal-9) from the bone marrow, blood, liver, spleen, and lungs of adult and neonatal mice. We also examined the effector functions of Gal-9(+)NK cells compared with their Gal-9(-) counterparts. Our results revealed that Gal-9(+)NK cells are more abundant in tissues, in particular, in the liver than in the blood and bone marrow. We found Gal-9 presence was associated with enhanced cytotoxic effector molecules granzyme B (GzmB) and perforin expression. Likewise, Gal-9 expressing NK cells displayed greater IFN-gamma and TNF-alpha expression than their negative counterparts under hemostatic circumstances. Notably, the expansion of Gal-9(+)NK cells in the spleen of mice infected with E. coli implies that Gal-9(+)NK cells may provide a protective role against infection. Similarly, we found the expansion of Gal-9(+)NK cells in the spleen and tumor tissues of melanoma B16-F10 mice. Mechanistically, our results revealed the interaction of Gal-9 with CD44 as noted by their co-expression/co-localization. Subsequently, this interaction resulted in enhanced expression of Phospho-LCK, ERK, Akt, MAPK, and mTOR in NK cells. Moreover, we found Gal-9(+)NK cells exhibited an activated phenotype as evidenced by increased CD69, CD25, and Sca-1 but reduced KLRG1 expression. Likewise, we found Gal-9 preferentially interacts with CD44(high) in human NK cells. Despite this interaction, we noted a dichotomy in terms of effector functions in NK cells from COVID-19 patients. We observed that the presence of Gal-9 on NK cells resulted in a greater IFN-gamma expression without any changes in cytolytic molecule expression in these patients. These observations suggest differences in Gal-9(+)NK cell effector functions between mice and humans that should be considered in different physiological and pathological conditions. Therefore, our results highlight the important role of Gal-9 via CD44 in NK cell activation, which suggests Gal-9 is a potential new avenue for the development of therapeutic approaches to modulate NK cell effector functions.
引用
收藏
页数:15
相关论文
共 50 条
  • [1] Profiling the role of galectin-9 in modulating the HA/CD44 interaction
    Durbin, Sarah
    Barkley, Rachel
    Jude, Laura
    Campbell, A.
    Snyder, Nicole
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2015, 249
  • [2] Galectin-9 induces osteoblast differentiation through the CD44/Smad signaling pathway
    Tanikawa, Rena
    Tanikawa, Takahisa
    Hirashima, Mitsuomi
    Yamauchi, Akira
    Tanaka, Yoshiya
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2010, 394 (02) : 317 - 322
  • [3] Galectin-9 Functionally Impairs Natural Killer Cells in Humans and Mice
    Golden-Mason, Lucy
    McMahan, Rachel H.
    Strong, Michael
    Reisdorph, Richard
    Mahaffey, Spencer
    Palmer, Brent E.
    Cheng, Linling
    Kulesza, Caroline
    Hirashima, Mitsuomi
    Niki, Toshiro
    Rosen, Hugo R.
    JOURNAL OF VIROLOGY, 2013, 87 (09) : 4835 - 4845
  • [4] ENHANCEMENT OF NATURAL-KILLER ACTIVITY BY AN ANTIBODY TO CD44
    TAN, PHS
    SANTOS, EB
    ROSSBACH, HC
    SANDMAIER, BM
    JOURNAL OF IMMUNOLOGY, 1993, 150 (03): : 812 - 820
  • [5] ENHANCEMENT OF NATURAL-KILLER ACTIVITY BY AN ANTIBODY TO CD44
    SANDMAIER, BM
    TAN, P
    SANTOS, E
    STORB, R
    EXPERIMENTAL HEMATOLOGY, 1992, 20 (06) : 730 - 730
  • [6] ENHANCEMENT OF NATURAL-KILLER ACTIVITY BY AN ANTIBODY TO CD44
    SANDMAIER, BM
    TAN, PHS
    SANTOS, EB
    JOURNAL OF CELLULAR BIOCHEMISTRY, 1993, : 352 - 352
  • [7] Secreted IgD Amplifies Humoral T Helper 2 Cell Responses by Binding Basophils via Galectin-9 and CD44
    Shan, Meimei
    Carrillo, Jorge
    Yeste, Ada
    Gutzeit, Cindy
    Segura-Garzon, Daniel
    Walland, A. Cooper
    Pybus, Marc
    Grasset, Emilie K.
    Yeiser, John R.
    Matthews, Dean B.
    van de Veen, Willem
    Comerma, Laura
    He, Bing
    Boonpiyathad, Tadech
    Lee, Haekyung
    Blanco, Julia
    Osborne, Lisa C.
    Siracusa, Mark C.
    Akdis, Mubeccel
    Artis, David
    Mehandru, Saurabh
    Sampson, Hugh A.
    Berin, M. Cecilia
    Chen, Kang
    Cerutti, Andrea
    IMMUNITY, 2018, 49 (04) : 709 - +
  • [8] Galectin-9 mediates neutrophil capture and adhesion in a CD44 and β2 integrin-dependent manner
    Iqbal, Asif J.
    Krautter, Franziska
    Blacksell, Isobel A.
    Wright, Rachael D.
    Austin-Williams, Shani N.
    Voisin, Mathieu-Benoit
    Hussain, Mohammed T.
    Law, Hannah L.
    Niki, Toshiro
    Hirashima, Mitsuomi
    Bombardieri, Michele
    Pitzalis, Costantino
    Tiwari, Alok
    Nash, Gerard B.
    Norling, Lucy, V
    Cooper, Dianne
    FASEB JOURNAL, 2022, 36 (01):
  • [9] CD44 IS A TRIGGER MOLECULE IN HUMAN NATURAL-KILLER-CELLS
    SCONOCCHIA, G
    TITUS, JA
    SEGAL, DM
    FASEB JOURNAL, 1994, 8 (04): : A199 - A199
  • [10] Galectin-9 inhibits CD44-hyaluronan interaction and suppresses a murine model of allergic asthma
    Katoh, Shigeki
    Ishii, Naoki
    Nobumoto, Atsuya
    Takeshita, Keisuke
    Dai, Shu-Yan
    Shinonaga, Rika
    Niki, Toshiro
    Nishi, Nozomu
    Tominaga, Akira
    Yamauchi, Akira
    Hirashima, Mitsuomi
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2007, 176 (01) : 27 - 35